指南与共识脑血管病

临床前缺血性卒中多中心试验(PRISM)联合声明:新机遇、挑战与建议

Preclinical Ischemic Stroke Multicenter Trials (PRISM) Collective Statement: Opportunities, Challenges, and Recommendations for a New Era.
指南 / 共识 · Stroke · 2025-09-11

该联合声明由参与多中心临床前随机对照试验(mpRCT)的专家提出,旨在缩小临床前卒中研究的转化差距。声明讨论了mpRCT的设计与实施考虑,包括样本量、统计设计、异质性、卒中模型选择、功能结局指标及网络基础设施等挑战,并强调机器学习、通用数据元素和治疗候选物选择的重要性。声明还探讨了向mpRCT平台过渡及数据共享的附带效益,希望启动关于mpRCT未来发展的持续讨论。

要点

  • mpRCT可增加样本量、采用稳健统计设计并纳入异质性,但需平衡标准化与异质性。
  • 卒中模型选择、功能结局指标及网络基础设施实施是mpRCT面临的主要挑战。
  • 机器学习、通用数据元素和合适治疗候选物的整合可最大化mpRCT效率与效用。

核心结论

  • mpRCT有望改善临床前卒中研究并弥合转化差距,但需在标准化与异质性间取得平衡并解决实施挑战。

研究设计与样本

  • 本声明基于参与mpRCT的专家经验,提出设计和执行mpRCT的考虑因素,未报告具体样本量或检索范围。

主要发现

  • mpRCT具有增加样本量、稳健统计设计、纳入异质性和标准化方案等优势。
  • mpRCT面临标准化与异质性平衡、卒中模型选择、结局指标及复杂网络基础设施实施等挑战。
  • 向mpRCT平台过渡有望促进疗法的持续评估。

临床怎么用

  • 临床前卒中研究可考虑采用mpRCT设计以提高转化预测可靠性。
  • 设计mpRCT时应关注卒中模型选择、生物学变量与合并症代表性、功能结局读出及 attrition 和死亡率处理。
  • 统计方面可考虑自适应序贯设计、协变量调整和缺失数据恰当处理。
  • 整合机器学习、通用数据元素和选择合适治疗候选物可提升mpRCT效率。
  • 数据共享实践可带来附带效益,促进临床前卒中研究改进。

局限性

  • 本声明为专家观点集合,旨在启动讨论,未提供系统评价或具体数据支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Preclinical stroke research faces a critical translational gap, with animal studies failing to reliably predict clinical efficacy. To address this, the field is moving toward rigorous, multicenter preclinical randomized controlled trials (mpRCTs) that mimic phase 3 clinical trials in several key components. This collective statement, derived from experts involved in mpRCTs, outlines considerations for designing and executing such trials. mpRCTs offer advantages such as increased sample sizes, robust statistical design, incorporation of heterogeneity, and standardized protocols, but they face challenges in finding the right balance between standardization and heterogeneity, appropriate stroke model selection, and outcome measures, as well as the implementation of complex network infrastructure. We discuss the importance of rigorous study design, including appropriate stroke models, representation of biological variables and comorbidities, functional outcome readouts, and handling of attrition and mortality. Statistical considerations such as adaptive sequential designs, covariate adjustments, and appropriate handling of missing data are also addressed. The integration of machine learning, the implementation of common data elements, and the selection of appropriate therapeutic candidates are crucial for maximizing the efficiency and utility of mpRCTs. Furthermore, the transition toward mpRCT platforms, akin to clinical trial platforms, holds promise for facilitating continuous evaluation of therapies. Finally, we discuss data-sharing practices and the collateral benefits of mpRCTs, emphasizing their potential to improve preclinical stroke research and bridge the translational gap. Altogether, we hope that this article will serve as a starting point for a lasting debate on the future of stroke mpRCTs and their evolution toward a universally accepted set of principles.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Ayata C, Bath PM, Planas AM, et al. Preclinical Ischemic Stroke Multicenter Trials (PRISM) Collective Statement: Opportunities, Challenges, and Recommendations for a New Era. Stroke. 2025. PMID: 40931817. doi:10.1161/STROKEAHA.125.052056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。